ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

Comparison of Platelet Function Tests during P2Y12 Inhibition

P.P. Wadowski1, J. Pultar1, C. Weikert1, B. Eichelberger2, I.M. Lang3, R. Koppensteiner1, S. Panzer2, T. Gremmel1,4

1Medical University of Vienna, Department of Internal Medicine II, Division of Angiology, Vienna, Austria, 2Medical University of Vienna, Department of Blood Group Serology and Transfusion Medicine, Vienna, Austria, 3Medical University of Vienna, Department of Internal Medicine II, Division of Cardiology, Vienna, Austria, 4Landesklinikum Mistelbach-Gänserndorf, Department of Internal Medicine I, Mistelbach, Mistelbach, Austria

Abstract Number: PB0004

Meeting: ISTH 2021 Congress

Theme: Arterial Thromboembolism » Acute Coronary Syndromes

Background: Data on the agreement between light transmission aggregometry (LTA) and multiple electrode aggregometry (MEA) in patients on the more potent P2Y12 inhibitors are missing so far.

Aims: Therefore, we investigated if the evaluation of the responsiveness to therapy by LTA can be replaced by MEA in 160 acute coronary syndrome (ACS) patients on dual antiplatelet therapy with aspirin and prasugrel or ticagrelor (n=80 each).

Methods: Platelet aggregation was measured using adenosine diphosphate (ADP) or arachidonic acid (AA) as agonists. Cut-off values for high on-treatment residual platelet reactivity (HRPR) to ADP and AA were defined according to previous studies showing an association of HRPR with the occurrence of adverse ischemic outcomes.

Results: ADP-inducible platelet reactivity by MEA correlated significantly with LTA ADP in prasugrel-treated patients (r=0.4, p<0.001), but not in those receiving ticagrelor (r=0.09; p=0.45). AA-inducible platelet aggregation by LTA and MEA did not correlate in prasugrel- and ticagrelor-treated patients. Sensitivity/specificity of HRPR by MEA to detect HRPR by LTA were 25%/99% for MEA ADP and 100%/79% for MEA AA in prasugrel-treated patients, and 0%/100% for MEA ADP and 70%/83% for MEA AA in ticagrelor-treated patients.

Conclusions: On-treatment residual ADP-inducible platelet reactivity by LTA and MEA shows a significant correlation in prasugrel- but not ticagrelor-treated patients. However, in both groups LTA and MEA revealed heterogeneous results regarding the classification of patients as responders or non-responders to P2Y12 inhibition. Accordingly, these tests are not interchangeable in the assessment of the response to antiplatelet therapy in ACS patients undergoing PCI. 
 

To cite this abstract in AMA style:

Wadowski PP, Pultar J, Weikert C, Eichelberger B, Lang IM, Koppensteiner R, Panzer S, Gremmel T. Comparison of Platelet Function Tests during P2Y12 Inhibition [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 2). https://abstracts.isth.org/abstract/comparison-of-platelet-function-tests-during-p2y12-inhibition/. Accessed May 20, 2022.

« Back to ISTH 2021 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/comparison-of-platelet-function-tests-during-p2y12-inhibition/

Simple Search

Supported By:

Bristol Myers Squibb and Pfizer

ISTH 2021 Congress site

Visit the official web site for the ISTH 2021 Virtual Congress »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2022 John Wiley & Sons, Inc. All Rights Reserved.
Wiley